Kestra Advisory Services, LLC Genmab A/S Transaction History

Kestra Advisory Services, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$25.13 - $30.27 $205,789 - $247,881	8,189 New	8,189 $205,000
Q4 2022 Jan 31, 2023	BUY	$33.8 - $47.06 $26,870 - $37,412	795 Added 7.2%	11,842 $501,000
Q3 2022 Nov 01, 2022	BUY	$31.52 - $373.61 $36,311 - $430,398	1,152 Added 11.64%	11,047 $355 Million
Q2 2022 Aug 12, 2022	BUY	$26.83 - $38.57 $17,734 - $25,494	661 Added 7.16%	9,895 $321,000
Q1 2022 Apr 26, 2022	BUY	$30.95 - $39.68 $6,035 - $7,737	195 Added 2.16%	9,234 $334,000
Q4 2021 Jan 20, 2022	SELL	$35.87 - $47.12 $63,489 - $83,402	-1,770 Reduced 16.38%	9,039 $357,000
Q3 2021 Oct 19, 2021	BUY	$41.55 - $48.72 $61,660 - $72,300	1,484 Added 15.91%	10,809 $472,000
Q2 2021 Jul 28, 2021	BUY	$32.88 - $44.57 $45,834 - $62,130	1,394 Added 17.58%	9,325 $380,000
Q1 2021 May 10, 2021	BUY	$30.92 - $44.4 $245,226 - $352,136	7,931 New	7,931 $260,000

240

52.6M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $14.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Kestra Advisory Services, LLC with notifications on news.